I don’t know much about pharmaceutical pricing or drug discovery to offer an informed opinion as to why it’s so expensive ($300/day) or whether that’s justified.
AstraZeneca’s patent expires in 2035 and as a cash cow ($2B in revenue) I would expect they continue to aggressively fight competitors in court.
Imatinib (the 1st gen drug of the same class) went generic a few years ago and is 99% cheaper now.
I assume we’ll see something similar with osimertinib but I can’t comment on whether there’s any secret sauce that makes it different.
Perhaps one of the pharma/biochem HN commenters can offer more insight.
AstraZeneca’s patent expires in 2035 and as a cash cow ($2B in revenue) I would expect they continue to aggressively fight competitors in court.
Imatinib (the 1st gen drug of the same class) went generic a few years ago and is 99% cheaper now.
I assume we’ll see something similar with osimertinib but I can’t comment on whether there’s any secret sauce that makes it different.
Perhaps one of the pharma/biochem HN commenters can offer more insight.